Objective: Clinical trials have failed to demonstrate a survival benefit of adjuvant chemotherapy in diffuse intrinsic pontine gliomas (DIPG). Radiation therapy (RT) is the only effective treatment thus far and reirradiation (rRT) has become an option at the time of progression. The aim of this study was to review the Canadian experience of DIPG rRT with a focus on the safety and possible efficacy of this approach.
INTRODUCTION
More than 90% of the children diagnosed with diffuse intrinsic pontine gliomas (DIPG) will succumb to their disease within 2 years of diagnosis. 1 Despite numerous clinical trials of chemotherapy, radiosensitizers, and biological modifiers, survival has remained unchanged With the lack of agents known to be active in newly diagnosed DIPG, 2 with inconsistent access to experimental therapies, with the knowledge that RT is the only treatment modality that has been shown to lengthen life after diagnosis of DIPG, 3 and with increasing evidence of the safety of reirradiation (rRT) in other pediatric brain tumors, 10, 11 there is growing interest in considering rRT for refractory or progressive DIPG. We report the Canadian experience of rRT of children with DIPG at the time of disease progression.
METHODS
Multicenter retrospective data collection was performed across Canada. All patients under 18 years who received rRT after progression of DIPG were included. Disease progression was defined as neurological deterioration confirmed by magnetic resonance imaging (MRI).
No restrictions were made in terms of therapy received before or after rRT. Any regimen of conventional RT at progression was permitted.
Clinical information was extracted from patient medical records.
The primary aim of the study was to analyze the time from progression to death (measured from date of progression to date of death) and overall survival (measured from date of first diagnosis to date of death) of the group. The reirradiated group was compared to a historic cohort of 46 consecutive patients with DIPG treated without rRT at the Hospital for Sick Children from 2000 to 2011.
Descriptive statistics were used to summarize patient and treatment characteristics, along with outcomes. The Kaplan-Meier method was used to determine distribution of survival. The log-rank test was used to explore for differences in survival between groups. Statistical analysis was performed using SPSS, version 20 (SPSS Inc., Chicago, IL).
This study was approved by the Institutional Review Board of each participating institution.
RESULTS
Between January 2011 and February 2016, 16 patients with progressive DIPG received rRT at six institutions across Canada. Median age at diagnosis was 5.87 years (range, 2.25-13 years). Median time from diagnosis to progression was 10.5 months (range, 4-37 months). Fourteen patients had local progression, one local + disseminated progression, and one disseminated progression. rRT started with a median of 26.5 days (range, 7-120) after first progression. Median time from diagnosis to rRT was 13 months (range, 4.7-38.9 months). Patient and treatment characteristics are listed in Table 1. rRT total dose and fractionation varied between institutions from 21.6 to 36 Gy (median dose 30.6 Gy). rRT was given focally in 88% of the patients. Two patients received whole brain rRT with 30.6 Gy due to disseminated progression. One patient who was reirradiated focally with 30.6 Gy had a second relapse 6 months after rRT and received a third course of rRT with 21.6 Gy. One patient had treatment for first progression with bevacizumab and irinotecan for 4 months before starting rRT. Only one patient received concomitant therapy during rRT (bevacizumab). Seven patients received chemotherapy after rRT including temozolomide, valproic acid, nimotuzumab, and bevacizumab or a combination of these.
All patients had neurological symptoms at progression. In 13 patients (81%), these neurological symptoms improved after rRT; in six patients, the recovery was full. An evaluation of dexamethasone use showed that six patients used none, nine were started on dexamethasone at progression and were either weaned by the end of rRT (n = 4) or were continued after rRT (n = 5), and there was no information in one patient. Ten patients had an MRI after rRT to assess tumor response. In eight patients, a radiological improvement was seen. One of the patients who had progression on MRI showed increase in size with evidence of necrosis within the tumor and survived 6 months after rRT. rRT was well tolerated by all children with the exception of one.
There were no side effects in 10 patients. 
DISCUSSION
Diffuse intrinsic pontine glioma continues to be a devastating disease with a fatal outcome. 12 Despite extensive research including recent genomic studies leading to the development of targeted trials, thus far no improvement in survival has been achieved. RT is the only treatment that has shown benefit in these patients, although it is essentially considered as palliative, since long-term survival is a rarity. 13 At the time of progression, most patients die within weeks or months with a progressive neurological decline and poor quality of life due to increasing disability. rRT, which has been safely used with evidence of survival benefit in other pediatric brain tumors such as ependymoma and medulloblastoma, 10, 11 has been recently proposed as a potential approach in children with progressive DIPG. 14 Three previous reports have described the outcome of patients whose treatment of recurrent disease included rRT. [14] [15] [16] Median time to progression after rRT was 5 months. 15 In the second report by investigators from Italy, rRT was built into a phase II study of radiation plus nimotuzumab and vinorelbine for newly diag- In our experience, clinical improvement was observed in all but three patients. These results confirm the benefit of this approach in a palliative setting. Interestingly, steroids were completely avoided in six patients and were discontinued in four patients by the end of the rRT.
Data on steroid usage are not available in all other reports, although this represents a major aspect of the benefit associated with rRT in this population. Similarly, evaluation of quality of life was lacking in these early reports. Quality of life data should be prospectively assessed when using this strategy since this information may be critical for parents confronted with a decision to proceed to rRT or supportive care.
Several aspects of DIPG rRT remain to be determined, including the optimal radiation dose and fractionation, and the minimal interval between the two courses of radiation. In our experience, no rRT was given if the interval between diagnosis and progression was less than 4 months. This may have excluded patients with more aggressive tumors. In the European experience, some patients were treated as early as 3 months after completion of initial radiation treatment, with no Grade 4-5 toxicity reported. 14 In early report of rRT, most patients received relatively low doses in the range of 20 Gy with evidence of clinical improvement. [14] [15] [16] In our experience, higher doses were used with no significant side effects when using 1.8 Gy fractionation, and 11 patients received more than 27 Gy in 1.8 Gy fractions with no evidence of increased toxicity. One patient received a second course of rRT that was well tolerated as previously reported. 17 The good tolerance of this technique maybe related to the relatively low-dose delivered per fraction (1.8 Gy) in most patients. Of our 16 patients, two received 30 Gy in 10 fractions. One suffered pontine necrosis with brainstem dysfunction and quadriparesis. This severe toxicity may have been related to the higher fraction size given in this case (3 Gy) and it is our recommendation that fraction sizes in the 1.8-2.0 Gy range should be used when delivering rRT in this context.
Diffuse intrinsic pontine glioma continues to be an incurable disease. As research continues to look for new treatment options, efforts should be made to find an effective treatment strategy in balance with quality of life after diagnosis. rRT may be an option for patients with relapse after conventional treatment. The tolerance of rRT combined with improvement in neurologic function suggests an acceptable quality of life, at least temporarily. Acknowledging the small number of patients in our study, in our experience, a dose of 30.6 Gy in 1.8 Gy fractions was well tolerated. It is unclear if additional chemotherapy adds benefit to these patients. However, the rationale for using chemother-apy is weak, since no chemotherapeutic agent has ever demonstrated a benefit in newly diagnosed patients. Future clinical trials of rRT should further assess the optimal dose, fractionation, the interval between courses of RT, and the quality of life associated with this strategy.
Prospective Canadian rRT protocols are in progress to address these questions.
